
BBT594
CAS No. 882405-89-2
BBT594( NVP-BBT594 )
Catalog No. M20783 CAS No. 882405-89-2
BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RETTreatment of cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 87 | In Stock |
![]() ![]() |
10MG | 140 | In Stock |
![]() ![]() |
25MG | 225 | In Stock |
![]() ![]() |
50MG | 356 | In Stock |
![]() ![]() |
100MG | 537 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameBBT594
-
NoteResearch use only, not for human use.
-
Brief DescriptionBBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RETTreatment of cancer.
-
DescriptionBBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RETTreatment of cancer.
-
In VitroNVP-BBT594 blocks the GDNF-mediated enhancement of MCF7-LTED cell viability in 2D culture and 3D colony formation. The addition of 10 pM E2, to mimic the E2 level in post-menopausal patients that have relapsed on AI treatment and ceased AI therapy, increases 3D colony formation of both MCF7 and MCF7-LTED cells, and this effect is efficiently reverted by NVP-BBT594. Parental T47D cells cultured in presence of low level E2, GFRα1/GDNF stimulation results in increased 3D colony formation, which is significantly reverted by NVP-BBT594. NVP-BBT594 targets GDNF-RET signaling and sensitizes MCF7-2A cells to letrozole treatment. NVP-BBT594 impairs GDNF-mediated RET downstream signaling and significantly enhances the antiproliferative effects of letrozole. NVP-BBT594 shows the highest suppression of GDNF-induced RET signaling, as assessed by RET, ERK1/2, AKT and ER phosphorylation. NVP-AST487 and NVP-BBT594 have comparable RET inhibitory activity in wild-type MCF7 cells.
-
In Vivo——
-
SynonymsNVP-BBT594
-
PathwayTyrosine Kinase
-
Targetc-RET
-
RecptorRET
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number882405-89-2
-
Formula Weight569.58
-
Molecular FormulaC28H30F3N7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:33 mg/mL (57.94 mM)
-
SMILESCC(=O)Nc1cc(Oc2ccc3c(c2)CCN3C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)ncn1
-
Chemical Name5-((6-acetamidopyrimidin-4-yl)oxy)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)indoline-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang Q Shi C Han L et al. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia[J]. Oncotarget 2018 9(8).
molnova catalog



related products
-
Enbezotinib
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
-
4-methyl-2-(4-(trifl...
4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid is a metabolite of GW 501516.
-
Compound TPX-0046
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.